The extended indications of the ® of The Pharmaceutical Administration of China have been approved by the State Drug Administration of China
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Baishi Meishi Guibao announced that its PD-1 inhibitor Odivo ® (Navuliyu monoantigen) has been approved by China's NationalDrug(http://Regulatory Authority to expand the indicationsthis adaptation certificate is applicable to patients with recurrent or metastatic head and neck squamous (SCCHN) who have developed disease progression during or after treatment with platinum-containing protocoland and whose tumor PD-L1 expression is positive (tumor cells expressing PD-L1As China's firstof immunocancerdrug (http://, O'Devos was the first to be approved in China in June 2018 for treatment of non-small cell lung cancer patientshead and neck squamous cancer is the second indication approved by Odivo after the priority review and approval of the Chinese Drug AdministrationWith this approval, Odivo became The first and currently the only PD-1 inhibitor in China to treat head and neck squamous cancer, marking the official entry of the treatment of head and neck squamous cancer in China into a new era of immunotherapy.Because of the special location of head and neck tumors, traditional therapies and tumors themselves will damage the function of the head and neck organs to a certain extent, affect ingestion and eating, resulting in their nutritional intake, psychologicalhealth(http://and social functions significantly impairedpatients are eager to see new treatment options that help them survive and improve their quality of life
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
